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Phosphoinositide-3 kinases (PI3Ks) are central signaling enzymes that are involved
in many aspects of immune cell function. PI3Kγ and PI3Kδ are the major isoforms
expressed in leukocytes. The role of PI3K isoforms in the resolution of inflammation
is still poorly understood. Here, we investigated the contribution of PI3Kγ and PI3Kδ to
the resolution of inflammation in a model of gout in mice.
Methods and Results: Experiments were performed in wild-type male C57/Bl6 mice.
Selective inhibitors of PI3K-γ (AS605240) or PI3Kδ (GSK045) were injected in the joint
12 h after injection of MSU crystals, hence at the peak of inflammation. Inhibition of
either PI3K isoform decreased number of neutrophils that migrated in response to
the injection of MSU crystals. This was associated with reduction of myeloperoxidase
activity and IL-1β levels in periarticular tissues and reduction of histological score.
Joint dysfunction, as seen by reduced mechanical hypernociception, was improved by
treatment with either inhibitor. The decrease in neutrophil numbers was associated with
enhanced apoptosis and efferocytosis of these cells. There was shortening of resolution
intervals, suggesting inhibition of either isoform induced the resolution of neutrophilic
inflammation. Blockade of PI3Kγ or PI3Kδ reduced Nuclear Factor kappa B (NF-κB)
activation. A pan-PI3K inhibitor (CL27c) reduced inflammation induced by MSU crystals
by a magnitude that was similar to that attained by the PI3Kγ or PI3Kδ selective inhibitors
alone.
Conclusion: Taken together, these results suggest that neutrophils can use PI3Kγ or
PI3Kδ to remain in the cavity and blockade of either isoenzyme is sufficient to induce
their apoptosis and resolve inflammation in a murine model of gout.
Keywords: gout, neutrophil, resolution of inflammation, phosphoinositide-3 kinases, inflammation
INTRODUCTION
Gout is a disease caused by the deposition of monossodium urate (MSU) crystals in the joint
and is characterized by swelling, redness, and intense pain. The prevalence and incidence of
gout are increasing in both developed and developing countries (So and Martinon, 2017). Acute
gouty inflammation is initiated by recognition of MSU crystals by resident cells that produce pro-
inflammatory mediators, especially IL-1β that is released by activation of the Nucleotide-binding
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domain Leucine-Rich-containing family Pyrin domain-
containing-3 (NLRP3) inflammasome (Martinon et al., 2006).
IL-1β has a critical role in orchestrating the inflammatory
reaction in response to MSU crystals and drives the production
of chemokines and neutrophil influx into the joint (Amaral et al.,
2012).Neutrophils are the main inflammatory cells recruited to
the joint and contribute to the amplification of the inflammatory
reaction, pain and progressive tissue damage (Busso and So,
2010). After migration, the lifespan of neutrophils is significantly
extended under inflammatory conditions (Kolaczkowska and
Kubes, 2013). Eventually, they undergo apoptosis and induce
clearance by phagocytic macrophages in a process termed
efferocytosis. Neutrophil apoptosis and subsequent efferocyosis
constitute an important step in the resolution of inflammation
and restoration of steady state (Serhan and Savill, 2005).
Resolution of inflammation, for many years, was considered
a passive response, which was associated with the clearance
of inflammatory stimulus, reduction of pro-inflammatory
mediators and prevention of leukocyte recruitment. Resolution
of inflammation is now considered an active process that
involves synthesis of pro-resolving mediators that actively
orchestrate the end of inflammation. In this context, the cardinal
signs of resolution involves not only limitation of leukocyte
migration and down regulation of chemokines and cytokines,
but also the turning off of signaling pathways associated with
leukocyte survival, which will eventually lead to leukocyte
apoptosis and its subsequent efferocytosis (Sugimoto et al.,
2016).
Phosphoinositide 3- kinase (PI3K) is a key regulator in
signaling pathways triggered by a large numbers of receptors on
the neutrophil surface (Hawkins et al., 2010). PI3Ks are enzymes
that catalyze the phosphorylation of inositol phospholipidis in the
third position of the inositol ring resulting in the formation of
phosphatidylinositol-3-phosphate [PI(3)P], phosphatidylinositol
3,4-biphosphate [PI(3,4)P2], and phosphatidylinositol 3,4,5-
trisphosphate [PI(3,4,5)P3], collectively termed 3′-PI lipids.
There are three classes of PI3K: Class I isoforms: class IA (p110α,
P110β, P110δ) and IB (PI3Kγ), Class II isoforms (PI3KC2α, β,
and γ) and Class III a single isoform (Hawkins and Stephens,
2015). Isoforms PI3Kδ and PI3Kγ, from class I, are highly
expressed in neutrophils suggesting that they have a particular
role in these cells. PI3Ks are involved in neutrophil chemotaxis
and it is also required for survival signals (Hawkins et al., 2010).
Indeed, previous studies with non-isoform selective inhibitors –
eg., Wortmaninn and LY294002 - have shown that blockade
of PI3Ks is associated with induction of the resolution of
inflammation in various models of inflammation (Pinho et al.,
2005; Sousa et al., 2009).
In the current study, we investigated the effect of delayed
inhibition of PI3Kγ or PI3Kδ, the major isoforms expressed
in neutrophils, in a model of gout in mice. Our results show
that blockade of PI3Ks induces resolution of inflammation by
increasing neutrophil apoptosis and eferocytosis. Of interest,
blockade of all PI3Ks or either PI3Kγ or PI3Kδ resulted in
similar degree of inhibition suggesting that function of both
PI3Kγ or PI3Kδ is necessary to guarantee neutrophil survival
in vivo.
MATERIALS AND METHODS
Mice
Male C57Bl/6 were obtained from the Center of bioterism
of Universidade Federal de Minas Gerais (UFMG) Brazil. All
mice were supplied with water and food ad libitum. Mice
were maintained in pathogen free conditions. This study was
carried out in accordance with the recommendations of the
law n◦ 11.794 from National Council for Control of Animals
Experimentation – CONCEA, Brazil. The protocol was approved
by the Animal Ethics Council – CEUA – at Universidade Federal
de Minas Gerais (protocol 2/2015). The total number of animals
used in the current study was 130, distributed in experiments
evaluating inhibition by selective PI3K inhibitor, for calculation
of resolution indices, for histology, functional analysis (pain)
and efferocytosis, as indicated in each relevant section of the
manuscript.
MSU Induced Gout
Crystals of MSU was prepared from uric acid (Sigma-Aldrich - St.
Louis MO, United States) as previously described (Amaral et al.,
2012). Mice under anesthesia (80:15 mg/kg ketamine:xylazine;
i.p., Syntec, São Paulo, Brazil) were injected into the tibiofemoral
knee joint with 100 µg of MSU crystals. The selective PI3K-γ
inhibitor (AS605240 – Echelor), the selective PI3K-δ inhibitor
[GSK045, (Gupta et al., 2016; Khan et al., 2017), kindly donated
by GlaxoSmithKline - GSK], the PI3Kγ/δ inhibitor [CL27c, a
pan-PI3K Inhibitor – (Pirali et al., 2017)] or vehicle were given
locally (intraarticular injection) at 12 h after the injection of MSU
crystals (see Figure 1). Inflammatory parameters were evaluated
at different time points after treatment, as indicated in each figure
legend. Mice were euthanized and the knee cavity washed with
PBS/BSA 3% (2 × 5 µL) to collect the cells. The total number
of leukocytes were determined using the newbauer chamber
after staining with Turk’s solution. The differential counts were
performed using standard morphologic criteria on a slide stained
with May-Grunwald-Giemsa. Periarticular tissues were collected
from the joints for evaluation of cytokines and myeloreproxidase
(MPO) activity.
Cytokines and Myeloperoxidase (MPO)
Activity
Periarticular tissue was collected and homogenized in PBS
containing anti-proteases, as previously described (Amaral et al.,
2012). The concentration of IL-1β, CXCL1, TNF-α, and IL-10 was
measured by ELISA assay in the supernatant of the homogenates
and according to the instructions of the manufacturer (R&D
systems). Results are expressed in pg/ml.
The myeloperoxidase activity assay was performed as
previously described (Amaral et al., 2012). Briefly, the pellet
from samples homogenized for cytokines measurements,
were homogenized with 0.05M NaH2PO4 containing 0.5%
of hexadecyltrimethyl-ammoniumbromide (HETAB; Signa-
Aldrich). Samples were frozen 3 times in liquid nitrogen and
centrifuged to collect the supernatant for MPO assay. The assay
used 3,3′, 5,5′-tetramethylbenzidine (TMB; Sigma-Aldrich) and
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FIGURE 1 | Dose response of PI3K-γ inhibitor in a MSU–induced gout inflammation. Mice were injected with MSU crystals (100 µg) into the tibiofemoral joint and
the treatment with different doses of PI3K-γ inhibitor was made locally, 12 h after MSU injection. Cells were harvested from the articular cavity at 18 h after MSU
injection. The number of total leukocytes (A) neutrophil (B), and mononuclear cell (C) were evaluated. Results are expressed as the number of leukocytes per cavity
and are shown as the mean ± SEM of five mice in each group from one experiment representative of two independent experiments. Significance was calculated
using ANOVA followed by Holm-Sidak’s multiple comparison test. The exactly p-value are shown in the figure.
was quantified at 450 nm in a spectrophotometer. Results are
expressed as absorbance.
Evaluation of Hypernociception
The mechanical hypernociception were evaluated as previously
described (Amaral et al., 2016) using an electronic pressure-
meter (Insight instruments, Ribeirão Preto, SP, Brazil). The
dorsiflexion-elicited withdrawal threshold was expressed in
grams (g) and used to infer behavioral responses associated with
experimental pain (hypernociception).
Calculation of Resolution Indices
The resolution indices were quantified as previously described
(Galvao et al., 2017). Briefly, cells were recovered from the
knee lavage at 12, 18, 24, and 36 h after MSU challenge. The
total cell count was determined using a Newbauer chamber and
differential leukocyte counts using standard morphologic criteria
on a slide stained with May-Grunwald-Giemsa. The Resolution
interval (Ri) was quantified by local kinetic of neutrophils
infiltration defining the time interval between Tmax (peak of the
infiltration) and T50 (time when numbers of neutrophils drops to
half of the peak).
Histological Analysis
Samples were processed as previously described (Queiroz-Junior
et al., 2011). Briefly, knee joints were collected, fixed in 10%
formol and decalcified for 30 days in 14% EDTA. Tissues were
included in paraffin, sectioned (5 µm) and stained with H&E.
Two sections of knee joints were examined and scored by a
pathologist (CQ-J) who was unaware of the experimental groups.
The parameters evaluated were: severity of synovial hyperplasia,
intensity and extension of inflammatory infiltrate, vascular
hyperemia, presence of inflammatory cells in the synovial cavity
and changes in tissue architecture. These criteria ranged from
0 to 8 points and the sum was used to obtain a histological
score.
Western Blot Analysis
Synovial tissue samples (20–40 mg tissue) were homogenized
using a cell lysis buffer, as described (Galvao et al., 2017).
Protein amounts were quantified with the Bradford assay
reagent from Bio-Rad (Hercules, CA, United States). Extracts
(40 µg) were separated by electrophoresis on a denaturing, 10%
polyacrylamide-SDS gel and electrotransferred to nitrocellulose
membranes. Membranes was incubated with specific primary
antibodies (anti-IκBα – Cell Signaling) and then incubated
with appropriated HRP-conjugated secondary antibody.
Immunoreactive bands were visualized by using an ECL
detection system, as described by the manufacturer (GE
Healthcare, Piscataway, NJ, United States). For loading control,
membranes were reprobed with anti-GAPDH (Sigma).
Assessment of Apoptosis and
Efferocytosis
Apoptosis and efferocytosis were assessed by flow cytometry,
as described previously (Dalli et al., 2013). Mice were injected
with MSU crystals and 12 h later they were treated locally
with PI3K inhibitors. For the apoptosis assays, the lavage of
the knee was performed 4 h after the treatment with drugs.
Cells were surface-stained for 30 min with anti-LY6G-BV421
antibody (eBioscience) and then labeled with annexin-V FITC
and PI, as an index of loss of nuclear membrane integrity
(PE Annexin V Apoptosis Detection Kit; BD PharmingenTM;
United States). For the efferocytosis assays, joint wasy was
performed 6 h after the treatment with PI3K inhibitors and
cells were surface-stained for 30 min with anti-F4/80-PECy7
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antibody (eBioscience). Then, cells were fixed for 10 min, treated
with 1× permeabilization wash (Cytofix/Cytoperm Kit; BD
Biosciences) and intracellularly stained with anti-Ly6G-BV421
antibody. Macrophage efferocytosis was assessed as a frequency
of macrophages containing neutrophils (F4/80+ Ly6G+ cells).
Statistical Analysis
The number of animals used in this study were determined
by using a statistical software (GPOWER 3.1.9.2) during the
preparation of the study design, considering the variation of
numbers of neutrophils in the knee lavage in our previous
publications. All results are presented as the mean ± SEM. The
analysis of the difference between two groups was performed
by two-tailed unpaired Student’s T test. Normalized data were
analyzed by one-way ANOVA, and differences between groups
were assessed using the Holm-Sidak’s multiple comparison
post hoc test. A p-value < 0.05 was considered significant.
Calculations were performed using the Prism 7.0 software
program for Windows (GraphPad software, San Diego, CA,
United States).
FIGURE 2 | Delayed treatment of PI3K-γ or PI3K-δ inhibitor in a MSU–induced gout inflammation induce timely resolution. Mice were injected with MSU crystals
(100 µg) into the tibiofemoral joint and the treatment with intraarticular injection (i.a.,) of 50 µM of PI3K-γ or PI3K-δ inhibitor, 12 h after MSU injection. Cells were
harvested from the articular cavity at 18, 24, and 36 h after MSU injection. The number of neutrophils and resolution indices were quantified (A). Of note:
ψmax = maximal number of neutrophils, ψ50 = 50% of the maximum number of neutrophils, Tmax = 12 h, the time point when neutrophil numbers reach maximum;
T50 MSU+AS605240 and MSU+GSK045 group ∼ 16 h, the time point when PMN numbers reduce to 50% of maximum; and resolution interval Ri MSU+AS605240
and MSU+GSK045 group ∼ 4 h, the time period when 50% PMN are lost from the articular cavity. Leukocytes counts 18 h after MSU injection (B) total leukocytes
numbers, (C) neutrophils, (D) mononuclear cells. Results are expressed as the number of leukocytes per cavity and are shown as the mean ± SEM of five mice in
each group from one experiment representative of two independent experiments. Significance was calculated using ANOVA followed by Holm-Sidak’s multiple
comparison test. The exactly p-value are shown in the figure. ##means p value < 0.01 compared with 18 h MSU injected.
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RESULTS
PI3K-γ Inhibitor Reverses Neutrophils
Recruitment in a Dose-Dependent
Manner
As previously reported, MSU crystals induced influx of
leukocytes, mainly neutrophils, into the knee joint at 18 h
after injection. The treatment with a specific PI3K-γ inhibitor,
AS605240, at the peak of the inflammation (i.e., 12 h after
administration of MSU crystals) was efficient to reduce the
number of accumulated neutrophils in a dose dependent manner
(Figure 1B). The highest dose caused the greatest reduction
of the number of neutrophils in the cavity and was used for
further experiments. No difference was observed in the number
of infiltrating mononuclear cells (Figure 1C).
Delayed Inhibition of PI3K-γ or PI3K-δ
Induce Timely Resolution of Neutrophilic
Inflammation
To determine the effects of the drugs on the kinetics of
neutrophil infiltration, we calculated the resolution indices (Ri)
after drug treatment. AS605240 or GSK045, a PI3K-δ inhibitor,
were injected intraarticular at the peak of acute inflammation
(i.e., 12 h) and cells from the synovial cavity harvested 6,
12, and 24 h after the drugs were given. The treatment with
AS605240 or GSK045 shortened the resolution interval by ∼5h.
These resolution indices Ri: RiMSU: ∼9 h; RiMSU+AS605240: ∼4 h;
RiMSU+GSK045: ∼4 h (Figure 2A) suggests an acceleration in
the resolution of acute inflammation. At 18 h after injection
of MSU crystals (6 h after injection of PI3K inhibitors), there
was significant reduction of the number of total leukocytes
(Figure 2B) and this reduction was due to inhibition of
neutrophils (Figure 2C), but not mononuclear cells (Figure 2D).
Overall, treatment with either AS605240 or GSK045 resulted in
similar degree of inhibition of the parameters observed.
Inhibition of PI3K-γ or PI3K-δ Reduced
Neutrophil Accumulation and Cytokines
That Mediates Joint Inflammation
To evaluate the inflammatory response after inhibition of
different PI3K isoforms, we investigated the accumulation of
neutrophils and production of pro-inflammatory cytokines in the
periarticular tissue of mice 18 h after injection of MSU crystals.
Both treatments reduced to a similar extent the accumulation
of neutrophils in periarticular tissues, as assessed by measuring
FIGURE 3 | Effects of PI3K-γ or PI3K-δ inhibition on neutrophil accumulation and pro-inflammatory mediators production. Myeloperoxidase activity in homogenized
periarticular tissue (A). IL-1β levels (B), CXCL1 (C), and TNF-α levels (D). Levels was measured by ELISA in supernatant of homogenized periarticular tissue. Results
are expressed as the number of leukocytes per cavity and are shown as the mean ± SEM of five mice in each group from one experiment representative of two
independent experiments. Significance was calculated using ANOVA followed by Holm-Sidak’s multiple comparison test. The exactly p-value are shown in the figure.
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MPO activity (Figure 3A). Injection of MSU crystals induced
an increase in levels of the pro-inflammatory mediators IL-1β,
CXCL1, and TNF-α in periarticular tissue. Overall, the treatment
with the PI3K-γ or PI3K-δ inhibitors caused a reduction of levels
of pro-inflammatory mediators but the effects of the PI3K-γ
inhibitor was more prominent than that of the PI3K-δ inhibitor
(Figures 3B–D).
Inhibition of PI3K-γ or PI3K-δ
Ameliorated Tissue Damage and
Mechanical Hypernociception
After having demonstrated the pro-resolving properties of
PI3K-γ or PI3K-δ inhibition, we turned our attention to the
possible impact of treatment on tissue damage. Histological
analysis of knees subjected to intraarticular injection of MSU
crystals showed moderate infiltration of leukocytes, focal
hyperplasia, and leukocytes in the synovial space 18 h after MSU
crystal injection. Inhibition of PI3K-γ or PI3K-δ decreased all the
observed parameters (Figure 4A) and resulted in overall decrease
of the histopathological score (Figure 4B).
Injection of MSU crystals induces mechanical
hypernociception, an index of joint dysfunction, as measured
by decrease in paw withdrawal threshold. The intraarticular
injection of the PI3K-γ or PI3K-δ inhibitors reduced to a similar
extent the hypernociception induced by the injection of MSU
crystals (Figure 4C).
Mechanistically, the Inhibition of PI3K-γ
or PI3K-δ Induced Neutrophils Apoptosis
and Efferocytosis
Next, we investigated whether induction of neutrophil apoptosis
and subsequent efferocytosis could account for the resolution
of MSU crystal-induced inflammation. For this purpose, mice
were treated intraarticularly with inhibitors at the peak of
inflammation and cells harvested from the knee cavity 4 h after
the treatment to evaluate apoptosis and 6 h after the treatment
FIGURE 4 | Effects of delayed treatment of PI3K-γ or PI3K-δ inhibitor on tissue damage and hypernociceptive responses. Representative photographs of
H&E-stained sections of knee from mice control (PBS), MSU challenge (MSU), mice challenge with MSU and post treated (12 h) with AS605240 (MSU+AS) and mice
challenge with MSU and post treated (12 h) with GSK045 (MSU+GSK045) (bars represent 400 µm in magnification of 40× and 50 µm in magnification of 400×) (A).
Graph shown histological score of joint injury of MSU crystal injected mice (B). Mechanical hypernociception was evaluated by an electronic pressure-meter 18 h
after the injection of MSU crystals (100 µg; ia) treated or not with AS605240 or GSK045 (γ or δ – 50 µM i.a.) (C). Results are expressed as the number of leukocytes
per cavity and are shown as the mean ± SEM of five mice in each group from one experiment representative of two independent experiments. Significance was
calculated using ANOVA followed by Holm-Sidak’s multiple comparison test. The exactly p-value are shown in the figure.
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to evaluate efferocytosis. We observed that treatment with
either inhibitor increased neutrophil apoptosis and efferocytosis
to a similar extent (Figures 5A,B). Noteworthy, these events
were associated with reduction in phosphorylation of IκBα,
an important regulator of the pro-survival molecule NFκB
(Figure 5C) (Original western blot Supplementary Figure S1).
Taken together, ours results clearly suggest that inhibition of
PI3K isoforms γ or δ accelerate apoptosis and efferocytosis
through down-modulation of NFκB leading to resolution of
inflammation.
Pan-PI3K Inhibition Produced the Same
Effects of Isolated Inhibition
A pan-PI3K inhibitor, CL27c, was used to investigate whether
inhibition of both PI3K isoforms could cooperate to achieve
greater induction of resolution of inflammation. The pan-PI3K
inhibition shortened the resolution interval by ∼5h, a result
similar to that achieved by inhibiting either enzyme alone
(Figure 6A). Noteworthy, the pan-PI3K inhibitor also induced
apoptosis and subsequent efferocytosis of neutrophils recruited
to the cavity (Figures 6B,C). Again, these effects were similar
in magnitude to those observed with treatment with either PI3K
inhibitor applied alone.
DISCUSSION
The major findings of the current study were: (i) delayed
inhibition of either PI3K-γ or PI3K-δ led to reduction of the
accumulation of neutrophils in the joint cavity in response to
the injection of MSU crystals. Reduction of neutrophil numbers
was associated with reduction in the levels of pro-inflammatory
mediators, decreased hypernociception and of tissue damage
induced by MSU crystals. (iii) The beneficial effects of the delayed
treatment with either inhibitor was secondary to their ability
to cause resolution of inflammation, as seen by the induction
of neutrophil apoptosis, their subsequent eferocytosis and faster
restoration of steady state in the cavity (Martinon et al., 2006).
FIGURE 5 | Effect of PI3K-γ inhibition or PI3K-δ inhibition on neutrophil apoptosis and efferocytosis in MSU-induced inflammation. Mice were injected with MSU
crystals (100 µg) into the tibiofemoral joint and 12 h later received an injection of AS605240 or GSK045 (50 µM, i.a.). Four hours after treatment, the cells were
collected to annexin V analysis (A). Efferocytosis was evaluated in mice injected with MSU crystals (100 µg) into the tibiofemoral joint and 12 h later received an
injection of AS605240 or GSK045. Knee was washed 18 h MSU injection and cells were surface-stained with anti-F4/80 for macrophages and then intracellularly
stained with anti-Ly6G for neutrophils (B). Results are expressed as the number of leukocytes per cavity and are shown as the mean ± SEM of five mice in each
group from one experiment representative of two independent experiments. Significance was calculated using ANOVA followed by Holm-Sidak’s multiple
comparison test. The exactly p-value are shown in the figure. (C) Expression of p-IκBα by Western Blot in synovial tissue collected 18 h after MSU injection. For
loading control, membrane was reprobed with anti-GAPDH.
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FIGURE 6 | Effect of pan-PI3K inhibition on neutrophil recruitment, apoptosis and efferocytosis in MSU-induced inflammation. Mice were injected with MSU crystals
(100 µg) into the tibiofemoral joint and the treatment with intraarticular injection (i.a.) of 50 µM of pan-PI3K inhibitor, 12 h after MSU injection. Cells were harvested
from the articular cavity at 18, 24, and 36 h after MSU injection. The number of neutrophils and resolution indices were quantified (A). Of note: ψmax = maximal
number of neutrophils, ψ50 = 50% of the maximum number of neutrophils, Tmax = 12 h, the time point when neutrophil numbers reach maximum; T50
MSU+pan-PI3K inhibitor group ∼ 16 h, the time point when PMN numbers reduce to 50% of maximum; and resolution interval Ri MSU+pan-PI3K inhibitor group
(γ/δ) ∼ 4 h, the time period when 50% PMN are lost from the articular cavity. (A) Apoptosis assay was evaluated 4 h after treatment, the cells were collected to
annexin V analysis (B). Efferocytosis was evaluated in mice injected with MSU crystals (100 µg) into the tibiofemoral joint and 12 h later received an injection of
pan-PI3K inhibitor. Cells were collected 18 h after MSU crystal injection and surface-stained with anti-F4/80 for macrophages and then intracellularly stained with
anti-Ly6G for neutrophils (C). Results are shown as the mean ± SEM of five mice in each group and are from one experiment representative of two independent
experiments. Significance was calculated in relation to the control group (two-tailed unpaired Student’s t-test). The exactly p-value are shown in the figure. ##means
p value < 0.01 compared with 18 h MSU injected.
Inhibition of either PI3K isoform was sufficient to attain full
inhibition of most inflammatory parameters. Indeed, there was
no additional resolution of inflammation when a pan-PI3K
inhibitor was used.
Inhibition of phosphatidylinositol 3-kinases (PI3Ks) have
been shown to inhibit the recruitment of neutrophils in
various models of inflammation (Ghigo et al., 2010). For
example, blockade of PI3K-γ using AS605240 supressed joint
inflammation and damage in a murine model of rheumatoid
arthritis (Camps et al., 2005). Similarly, pharmacological
blockade of PI3K-δ in K/BxN serum transfer model of arthritis
reduced the overall extent of inflammation (Randis et al.,
2008). We have shown that inhibition of both PI3K-γ and
PI3K-δ was necessary for prevention of the recruitment of
neutrophils in vivo, showing these enzymes played a redundant
role in CXCL1-mediated neutrophil influx (Pinho et al., 2007).
Other studies have shown that non-selective inhibition of PI3K
isoforms induced resolution of inflammation (Pinho et al.,
2005; Sousa et al., 2009). Different from anti-inflammatory
therapies that control inflammation by blocking key pro-
inflammatory mediators that are expressed in the initial phase
of the inflammation, pro-resolving therapies involve modifying
the course of an established inflammation by reducing the time
and accelerating the resolution (Serhan et al., 2007; Fullerton
and Gilroy, 2016). Here, we show for the first time that delayed
treatment with selective inhibitors for PI3K-γ or PI3K-δ affected
the resolution of inflammation, by reducing the time necessary
to decrease 50% of neutrophil from the maximal number,
demonstrating the potential pro-resolving properties of selective
PI3K inhibition.
Inhibition of class Ia PI3K, with non-selective inhibitors,
potentially downregulate cytokines generation in neutrophils
(Fortin et al., 2011). The interaction of MSU crystals with
neutrophil leads to activation of class Ia PI3K that is involved
in neutrophil degranulation (Popa-Nita et al., 2007). In gout,
neutrophils are largely responsible for tissue damage caused by
excessive release of granules into the synovial fluid (Dalbeth and
Haskard, 2005). In addition to tissue damage, pain experienced
by gouty patients during acute gout attack are the single most
common reasons for these patients to seek medical care (Ruiz-
Miyazawa et al., 2018). Mechanical hypernociceptive response,
an index of inflammatory pain, is associated with high number
of neutrophils and increased levels of IL-1β (Amaral et al.,
2012; Galvao et al., 2017). Here, treatment with inhibitors of
either isoforms was sufficient to reduce the secretion of pro-
inflammatory cytokines, and this was associated with reduced
number of neutrophils in the periarticular tissue (MPO), reduced
tissue damage and pain associated with MSU crystal-induced
inflammation.
Previous studies have shown that non-selective PI3K
inhibitors induced resolution of inflammation by increasing
apoptosis of eosinophils (Pinho et al., 2005; Sousa et al., 2009) and
neutrophils (Lopes et al., 2011) in sites of inflammation induced
by various stimuli. The clearance of apoptotic granulocytes
is mostly mediated by efferocytosis in inflamed tissue
(Greenlee-Wacker, 2016). Here, we clearly show that selective
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blockade of PI3K-γ or PI3K-δ was sufficient to induce
effectively apoptosis of neutrophils and induced their subsequent
efferocytosis in a murine model of gout. Together with the
reduction in resolution intervals, our results clearly show
that inhibition of either enzyme will induce resolution of
inflammation, suggesting that neutrophils may use PI3K-γ or
PI3K-δ to remain at sites of inflammation in vivo.
Induction of the resolution of inflammation by treatment with
a pan-PI3K inhibitor was similar in magnitude to that attained
with either PI3K-γ or PI3K-δ inhibition separately. These results
concur with the idea that neutrophils can use either PI3K-γ or
PI3K-δ to remain at sites of inflammation. NF-κB appears to
be a major transcription factor involved in the persistence of
neutrophils at sites of inflammation (Nathan, 2002; Lawrence,
2009). Indeed, we have shown that blockade of NF-κB resolve
inflammation in various models of inflammation (Vago et al.,
2015, 2016; Barroso et al., 2017), including in a model of gout
(Vieira et al., 2017). Other studies have shown that lipoxin A4
may modulate neutrophil infiltration by reducing the activation
of NF-κB (Devchand et al., 2003, 2005). Importantly, non-
selective inhibition of PI3K decreased NF-κB p65 translocation
to the nucleus, suggesting that NF-κB is downstream of PI3K
(Lopes et al., 2011). Our results clearly show that inhibition of
either PI3K-γ or PI3K-δ reduced activation of NF-κB in synovial
tissues. Therefore, it appears that a major mechanism by which
inhibition of PI3K controls neutrophil persistence in tissues is via
control of NF-κB activation.
Taken together, our results show that inhibition of PI3K-γ or
PI3K-δ isoforms induce resolution of inflammation in a murine
model of gout. There was characterized by neutrophil apoptosis
and increased efferocytosis and consequent reduction of pro-
inflammatory mediators, hypernociception and tissue damage. It
is unclear why both PI3K-γ and PI3K-δ are necessary to maintain
neutrophil survival in the cavity; i.e., Blockade of either enzyme
is sufficient to attain faster resolution of inflammation. Moreover,
it is unclear whether blockade of these enzymes will translate into
resolution of inflammation in more complex and chronic models
of inflammation. Regardless of limitation, our results clearly
show that PI3K-γ or PI3K-δ are needed to maintain neutrophil
persistence in inflammatory infiltrates.
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